ID   U2OS EZHIP KO
AC   CVCL_C8V6
SY   C67-KO U2OS
DR   Wikidata; Q123033671
RX   PubMed=33186520;
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 33738; EZHIP.
CC   Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0042 ! U2OS
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=33186520; DOI=10.1016/j.ccell.2020.10.009;
RA   Han J.-C., Yu M., Bai Y.-Q., Yu J.-Z., Jin F., Li C., Zeng R.,
RA   Peng J.-H., Li A., Song X.-M., Li H., Wu D.-Q., Li L.;
RT   "Elevated CXorf67 expression in PFA ependymomas suppresses DNA repair
RT   and sensitizes to PARP inhibitors.";
RL   Cancer Cell 38:844-856.e7(2020).
//